Enfortumab vedotin news

All news on Enfortumab vedotin (also known as Padcev): plants, production capacities, investments and involved companies.

12 June 2026

Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with WELIREG for adjuvant ccRCC

FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.

Who will be producing Enfortumab vedotin in the future?

Find out with chemXplore Alpha

Learn more